MX2008013039A - Metodo para aliviar la queratoconjuntivitis sicca. - Google Patents

Metodo para aliviar la queratoconjuntivitis sicca.

Info

Publication number
MX2008013039A
MX2008013039A MX2008013039A MX2008013039A MX2008013039A MX 2008013039 A MX2008013039 A MX 2008013039A MX 2008013039 A MX2008013039 A MX 2008013039A MX 2008013039 A MX2008013039 A MX 2008013039A MX 2008013039 A MX2008013039 A MX 2008013039A
Authority
MX
Mexico
Prior art keywords
alleviating
keratoconjunctivitis sicca
tear production
compound
topical
Prior art date
Application number
MX2008013039A
Other languages
English (en)
Inventor
Joel Bernstein
Original Assignee
Winston Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Winston Lab Inc filed Critical Winston Lab Inc
Publication of MX2008013039A publication Critical patent/MX2008013039A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención describe un método mejorado para aumentar la producción de lágrimas mediante la administración intranasalmente de una cantidad terapéuticamente efectiva de un compuesto capsaicinoide a pacientes con una producción deficientes de lágrimas. La incorporación opcional en la formulación intranasal de un corticosteroide tópico o compuesto anestésico tópico se usa para reducir la picazón y quemazón nasal transiente que a menudo pueden acompañar la administración intranasal de los capsaicinoides.
MX2008013039A 2007-10-05 2007-10-08 Metodo para aliviar la queratoconjuntivitis sicca. MX2008013039A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/868,286 US20090093446A1 (en) 2007-10-05 2007-10-05 Method for alleviating keratoconjunctivitis sicca
PCT/US2007/080707 WO2009045224A1 (en) 2007-10-05 2007-10-08 Method for alleviating keratoconjunctivitis sicca

Publications (1)

Publication Number Publication Date
MX2008013039A true MX2008013039A (es) 2009-06-05

Family

ID=40523784

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008013039A MX2008013039A (es) 2007-10-05 2007-10-08 Metodo para aliviar la queratoconjuntivitis sicca.

Country Status (13)

Country Link
US (1) US20090093446A1 (es)
EP (1) EP2094256A4 (es)
JP (1) JP2009545634A (es)
KR (1) KR20090080017A (es)
CN (1) CN101616663A (es)
AR (1) AR068669A1 (es)
AU (1) AU2007349197A1 (es)
BR (1) BRPI0710595A2 (es)
CA (1) CA2644733A1 (es)
IL (1) IL198657A0 (es)
MX (1) MX2008013039A (es)
NZ (1) NZ571467A (es)
WO (1) WO2009045224A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11166925B2 (en) 2018-08-23 2021-11-09 Elorac, Inc. Method for alleviating keratoconjunctivitis sicca

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019204A2 (en) * 2010-08-03 2012-02-09 Dynova Laboratories, Inc. Therapeutic agent for intranasal administration and method of making and using same
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
WO2012068247A1 (en) 2010-11-16 2012-05-24 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treatment of dry eye
ES2854732T3 (es) * 2011-07-07 2021-09-22 Eva Millqvist Producto antitusivo
WO2014031964A1 (en) * 2012-08-24 2014-02-27 Vr1, Inc. Composition for the treatment of migraine headaches
US10155108B2 (en) 2013-04-19 2018-12-18 Oculeve, Inc. Nasal stimulation devices and methods
BR112017008097B1 (pt) 2014-10-20 2023-03-28 Oyster Point Pharma, Inc Método para tratar condições oculares
BR112017008267A2 (pt) * 2014-10-22 2017-12-19 Oculeve Inc dispositivos e métodos para tratar olho seco
JP7090551B2 (ja) 2016-04-07 2022-06-24 オイスター ポイント ファーマ インコーポレイテッド 眼状態の治療方法
CA3022683A1 (en) 2016-05-02 2017-11-09 Oculeve, Inc. Intranasal stimulation for treatment of meibomian gland disease and blepharitis
TW202019424A (zh) * 2018-07-10 2020-06-01 美商奧伊斯特普安生物製藥公司 治療眼部症狀之方法
CN112384208A (zh) * 2018-08-23 2021-02-19 埃洛拉克有限公司 用于缓解干燥性角膜结膜炎的方法和组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5134166A (en) * 1988-12-02 1992-07-28 Genderm Corporation Method for treating nasal disorders and headaches
CA2017383A1 (en) * 1989-06-08 1990-12-08 Raymond R. Martodam Use of vanilloids for the treatment of respiratory diseases or disorders
US5063060A (en) * 1989-12-19 1991-11-05 Cisco Limited Partnership Compositions and method for treating painful, inflammatory or allergic disorders
ATE178208T1 (de) * 1993-09-30 1999-04-15 Medichemie Ag Capsaicin enthaltendes arzneimittel zur behandlung chronischer rhinopathie
CH690023A5 (de) * 1996-02-02 2000-03-31 Medichemie Ag Mittel zur Behandlung krankhafter Zellveränderungen der Nasenschleimhaut.
ZA99733B (en) * 1998-01-30 1999-08-02 R Tech Ueno Ltd Ophthalmic composition.
JP4653516B2 (ja) * 2004-02-27 2011-03-16 扶桑薬品工業株式会社 涙液分泌促進ペプチドおよびその組成物
DE102004063363A1 (de) * 2004-06-28 2006-01-19 Weber, Erhard, Dr. Capsaicin-haltige Arzneien zur Behandlung von Bronchial-Infekten und Allergien
AU2005309586A1 (en) * 2004-11-24 2006-06-01 Algorx Pharmaceuticals, Inc. Capsaicinoid gel formulation and uses thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11166925B2 (en) 2018-08-23 2021-11-09 Elorac, Inc. Method for alleviating keratoconjunctivitis sicca
US11478439B2 (en) 2018-08-23 2022-10-25 Elorac, Inc. Method for alleviating keratoconjunctivitis sicca

Also Published As

Publication number Publication date
EP2094256A1 (en) 2009-09-02
BRPI0710595A2 (pt) 2011-08-16
CN101616663A (zh) 2009-12-30
JP2009545634A (ja) 2009-12-24
AR068669A1 (es) 2009-11-25
AU2007349197A1 (en) 2009-04-23
IL198657A0 (en) 2010-02-17
CA2644733A1 (en) 2009-04-05
WO2009045224A1 (en) 2009-04-09
US20090093446A1 (en) 2009-04-09
KR20090080017A (ko) 2009-07-23
NZ571467A (en) 2009-03-31
EP2094256A4 (en) 2009-11-11

Similar Documents

Publication Publication Date Title
MX2008013039A (es) Metodo para aliviar la queratoconjuntivitis sicca.
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
MY139577A (en) Anti-inflammatory androstane derivative
EA031157B9 (ru) Вводимая перорально кортикостероидная композиция
WO2008157537A3 (en) Compositions and methods of use for treating or preventing lipid related disorders
WO2012116290A3 (en) Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
MX2010001236A (es) Derivados de 5-fenil-isoxazol-3-carboxamida como moduladores del receptor de potencial transitorio v1 (trpv1).
MY160074A (en) Protopanaxadiol-type ginsenoside compositions and uses thereof
IL221646A (en) Topical preparations containing an enantiomer (s) of Spiro-Oxandol type substance and used as drugs for sodium channel inhibition
MX2010006284A (es) Formulaciones farmaceuticas de fenilefrina y composiciones para la absorcion transmucosal.
NZ599136A (en) Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors
WO2012027693A3 (en) Pharmaceutical compositions comprising poh derivatives
TW200603787A (en) Topical preparations containing ambroxol
MX2010009623A (es) Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
WO2006047476A3 (en) Therapeutic and delivery methods of prostaglandin ep4 agonists
MX2012013212A (es) Forma farmaceutica oral resistente al alcohol.
WO2011141929A3 (en) Aqueous pharmaceutical compositions of fluticasone and olopatadine
MY192033A (en) Method of dosing and use of soft anticholinergic esters
WO2007134241A3 (en) Nasal delivery of therapeutic agents using tight junction agonists
HK1176318A1 (en) Injection device
RU2011101151A (ru) Интраназальные композиции, содержащие деконгестант и кортикостероид
MX2010009625A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
NZ594210A (en) Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma
MX347927B (es) Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
WO2009015485A8 (en) Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal